
FDA D.I.S.C.O. Burst Edition: FDA approval of Retevmo (selpercatinib) for advanced or metastatic RET fusion-positive thyroid cancer
0:00
4:00
Listen to a soundcast of the May 29, 2024, FDA approval of Retevmo (selpercatinib) for patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
More episodes from "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Don't miss an episode of “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” and subscribe to it in the GetPodcast app.